Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
Year: 2022
Type: article
Study design: Observational Study
Source: Blood
Authors: Veit L Buecklein, Ariel Perez-Perez, Kai Rejeski, Gloria Iacoboni, Vindi Jurinovic, Udo Holtick, Olaf Penack, Soraya Kharboutli, Viktoria Blumenberg, Josephine Ackermann, Lisa Frölich, Grace Johnson, Kedar Patel, Brian Arciola, Christian Schmidt, Omar Albanyan, Philipp Gödel, Eva Hoster, Lars Bullinger, Andreas Mackensen, Frederick L. Locke, Michael von Bergwelt, Pere Barba, Michael D. Jain, Marion Subklewe
Institutions: LMU Klinikum, Ludwig-Maximilians-Universität München, German Cancer Research Center, Deutsches Konsortium für Translationale Krebsforschung, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, University of Cologne, University Hospital Cologne, Charité - Universitätsmedizin Berlin, Universitätsklinikum Erlangen, University of South Florida, Moffitt Cancer Center, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitat Autònoma de Barcelona
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310108900